一种新的血液测试比CT扫描早发现肺癌, 通过使用先进的纳米技术识别微小的癌症信号, 但还没有为患者提供。 A new blood test detects lung cancer earlier than CT scans by identifying tiny cancer signals using advanced nanotech, but it's not yet available for patients.

深圳大学研究人员开发了一项新的血液测试,利用一种光基传感器,结合DNA纳米技术、CRIPR和量子点,确定痕量癌症生物标记,从而比传统成像更早发现肺癌。 A new blood test developed by Shenzhen University researchers detects lung cancer earlier than traditional imaging by identifying trace cancer biomarkers using a light-based sensor combining DNA nanotechnology, CRISPR, and quantum dots. 该方法在光盘中公布,在实际病人血清样本中仅从几个分子中成功检测到信号,从而能够在肿瘤出现在CT扫描中之前进行早期诊断。 The method, published in Optica, successfully detected signals from just a few molecules in real patient serum samples, enabling early diagnosis before tumors appear on CT scans. 它可以允许例行验血,通过经常的生物标志监测改善治疗的个性化,并减少对成像的依赖。 It could allow for routine blood screenings, improve treatment personalization through frequent biomarker monitoring, and reduce reliance on imaging. 研究人员认为,该技术最终可能导致对癌症和其他疾病进行便携式、无障碍的检测,尽管该技术仍处于早期阶段,尚不能用于临床使用。 Researchers believe the technology may eventually lead to portable, accessible tests for cancer and other diseases, though it remains in early stages and is not yet available for clinical use.